| Theme | The concepts of the new JSDT clinical guideline on CKD-MBD | |
|---|---|---|
| Title | Management of CKD-MBD in kidney transplant recipients | |
| Publish Date | 2013/01 | |
| Author | Naohiko Fujii | Research and Medical Center for Kidney Disease and Transplantation, Hyogo Prefectural Nishinomiya Hospital |
| Author | Ayako Okuno | Research and Medical Center for Kidney Disease and Transplantation, Hyogo Prefectural Nishinomiya Hospital |
| Author | Sayoko Yonemoto | Research and Medical Center for Kidney Disease and Transplantation, Hyogo Prefectural Nishinomiya Hospital |
| Author | Hidefumi Kishikawa | Research and Medical Center for Kidney Disease and Transplantation, Hyogo Prefectural Nishinomiya Hospital |
| Author | Kenji Nishimura | Research and Medical Center for Kidney Disease and Transplantation, Hyogo Prefectural Nishinomiya Hospital |
| Author | Yasuji Ichikawa | Research and Medical Center for Kidney Disease and Transplantation, Hyogo Prefectural Nishinomiya Hospital |
| [ Summary ] | CKD-MBD is commonly observed in the dialysis and pre-dialysis periods. It is often underestimated in kidney transplant recipients (KTRs). The pathophysiology of this condition is complicated and many times starts before transplantation. However, it is characterized by drastic changes in laboratory parameters soon after transplantation and uncoupling of bone mineral metabolism induced following immunosuppressive therapy and progressive renal dysfunction. Because we do not have any effective solution for treatment during the post-transplant period, the legacy effect of CKD-MBD gained during the dialysis period is rather important. Thus, long-term management of CKD-MBD is essential. In this section, we first introduce the pathophysiology of CKD-MBD in KTRs along with the new Japanese guideline for CKD-MBD in KTRs. We then reflect on what health care providers should take into account in the course of transplantation. | |